Thalidomide Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:420478187
Width:200
Chirality:Racemic mixture
Tradename:Contergan, Thalomid, others
Licence Eu:yes
Dailymedid:Thalidomide
Licence Us:Thalidomide
Pregnancy Au:X
Routes Of Administration:By mouth
Atc Prefix:L04
Atc Suffix:AX02
Legal Au:S4
Legal Br:C3
Legal Ca:Rx-only
Legal Uk:POM
Legal Us:Rx-only
Legal Us Comment:[1]
Legal Eu:Rx-only
Legal Eu Comment:[2] [3]
Bioavailability:90%
Protein Bound:55% and 66% for the (R)-(+)- and (S)-(−)-enantiomers, respectively[4]
Metabolism:Liver (minimally via CYP2C19-mediated 5-hydroxylation; mostly via non-enzymatic hydrolysis at the four amide sites)
Elimination Half-Life:5–7.5 hours (dose-dependent)
Excretion:Urine, feces and semen
Cas Number:50-35-1
Pubchem:5426
Iuphar Ligand:7327
Drugbank:DB01041
Chemspiderid:5233
Unii:4Z8R6ORS6L
Kegg:D00754
Chebi:9513
Chembl:468
Synonyms:α-Phthalimidoglutarimide
C:13
H:10
N:2
O:4
Smiles:O=C1c2ccccc2C(=O)N1C3CCC(=O)NC3=O
Stdinchi:1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)
Stdinchikey:UEJJHQNACJXSKW-UHFFFAOYSA-N

Thalidomide, sold under the brand names Contergan and Thalomid among others, is an oral medication used to treat a number of cancers (e.g., multiple myeloma), graft-versus-host disease, and many skin disorders (e.g., complications of leprosy such as skin lesions).[5] [6] [7] Thalidomide has been used to treat conditions associated with HIV: aphthous ulcers, HIV-associated wasting syndrome, diarrhea, and Kaposi's sarcoma, but increases in HIV viral load have been reported.[5]

Common side effects include sleepiness, rash, and dizziness.[5] Severe side effects include tumor lysis syndrome, blood clots, and peripheral neuropathy.[8] Thalidomide is a known human teratogen and carries an extremely high risk of severe, life-threatening birth defects if administered during pregnancy. It causes skeletal deformities such as amelia (absence of legs and/or arms), absence of bones, and phocomelia (malformation of the limbs). A single dose of thalidomide, regardless of dosage, is enough to cause teratogenic effects.[5]

Thalidomide was first marketed in 1957 in West Germany, where it was available over the counter.[9] When first released, thalidomide was promoted for anxiety, trouble sleeping, "tension", and morning sickness.[10] [11] While it was initially thought to be safe in pregnancy, concerns regarding birth defects arose, resulting in its removal from the market in Europe in 1961.[9] [10] The total number of infants severely harmed by thalidomide use during pregnancy is estimated at over 10,000, possibly 20,000, of whom about 40% died around the time of birth.[5] [10] Those who survived had limb, eye, urinary tract, and heart problems.[9] Its initial entry into the US market was prevented by Frances Kelsey, a reviewer at the FDA.[11] The birth defects caused by thalidomide led to the development of greater drug regulation and monitoring in many countries.[9] [11]

It was approved in the United States in 1998 for use as a treatment for cancer.[5] It is on the World Health Organization's List of Essential Medicines.[12] [13] It is available as a generic medication.[8] [14]

Medical uses

Thalidomide is used as a first-line treatment for multiple myeloma in combination with dexamethasone or with melphalan and prednisone to treat acute episodes of erythema nodosum leprosum, as well as for maintenance therapy.[15] [16]

The bacterium that causes tuberculosis (TB) is related to leprosy. Thalidomide may be helpful in some cases where standard TB drugs and corticosteroids are not sufficient to resolve severe inflammation in the brain.[17] [18]

It is used as a second-line treatment to manage graft-versus-host disease and aphthous stomatitis in children and has been prescribed for other conditions in children, including actinic prurigo and epidermolysis bullosa; the evidence for these uses is weak.[19] It is recommended only as a third line treatment in graft-versus-host-disease in adults because of lack of efficacy and side effects observed in clinical trials.[20] [21]

Contraindications

Prescriptions of thalidomide are accompanied by strict measures to avoid any possibility of use during pregnancy, and thalidomide should be avoided in women wanting to conceive.[22] In the United States, the prescribing doctor is required to ensure that contraception is being used, and that regular pregnancy tests are taken.[16] [15]

Adverse effects

See also: List of thalidomide side effects. Thalidomide causes birth defects.[15] [16] [23] [24] The U.S. Food and Drug Administration (FDA) and other regulatory agencies have approved marketing of the drug only with an auditable risk evaluation and mitigation strategy that ensures that people using the drug are aware of the risks and avoid pregnancy; this applies to both men and women, as the drug can be transmitted in semen.[23] [22]

There is a high risk that thalidomide can cause excessive blood clots. There is also a high risk that thalidomide can interfere with production of several types of new blood cells, creating a risk of infection via neutropenia, leukopenia, and lymphopenia, and risks that blood will not clot via thrombocytopenia. There is also a risk of anemia via lack of red blood cells. The drug can also damage nerves, causing potentially irreversible peripheral neuropathy.[15] [16]

Thalidomide has several adverse cardiovascular effects, including risk of heart attacks, pulmonary hypertension, and changes in heart rhythm, such as syncope, bradycardia, and atrioventricular block.[15] [16]

Thalidomide can cause liver damage and severe skin reactions like Stevens–Johnson syndrome. It tends to make people sleepy, which creates risk when driving and operating other machinery. As it kills cancer cells, it can cause tumor lysis syndrome. Thalidomide can prevent menstruation.[15] [16]

In addition, very common (reported in more than 10% of people) adverse effects include tremor, dizziness, tingling, numbness, constipation, and peripheral edema.[15] [16]

Common adverse effects (reported by 1–10% of people) include confusion, depressed mood, reduced coordination, heart failure, difficulty breathing, interstitial lung disease, lung inflammation, vomiting, dry mouth, rashes, dry skin, fever, weakness, and a sense of unwellness.[15] [16]

Interactions

There are no expected pharmacokinetic interactions between thalidomide and other medicines due to its neutral effects on P-glycoprotein and the cytochrome P450 family. It may interact with sedatives due to its sedative action and bradycardic agents, like beta-blockers, due to its bradycardia-inducing effects. Risk of peripheral neuropathy may be increased by concomitant treatment of thalidomide with other agents known to cause peripheral neuropathy.[25] The risk of venous thromboembolisms with thalidomide seems to be increased when patients are treated with oral contraceptives or other cytotoxic agents (including doxorubicin and melphalan) concurrently. Thalidomide may interfere with various contraceptives, and hence it is advised that women of reproductive age use at least two different means of contraception to ensure that no child will be conceived while they are taking thalidomide.[15] [16] [25]

Overdose

As of 2013, eighteen cases of overdoses had been reported with doses of up to 14.4 grams, none of them fatal.[25] No specific antidote for overdose exists and treatment is purely supportive.[25]

Pharmacology

The precise mechanism of action for thalidomide was not known until the twenty-first century,[26] although efforts to identify thalidomide's teratogenic action generated more than 2,000 research papers and the proposal of 15 or 16 plausible mechanisms by 2000.[27] The primary mechanism of action of thalidomide and its analogs in both their anti-cancer and teratogenic effects is now known to be as cereblon E3 ligase modulators.[26] [28] [29] [30]

Thalidomide also binds to and acts as an antagonist of the androgen receptor and hence is a nonsteroidal antiandrogen of some capacity.[31] In accordance, it can produce gynecomastia and sexual dysfunction as side effects in men.[32]

Chirality and biological activity

Thalidomide is provided as a racemic mixture of two enantiomers; while there are reports that only one of the enantiomers may cause birth defects, the body converts each enantiomer into the other through mechanisms that are not well understood.[23] The (R)-enantiomer has the desired sedative effect while the (S)-enantiomer harbors embryo-toxic and teratogenic effect. Attempting to extract solely R-thalidomide does not remove the risk of birth defects, as it was demonstrated that the "safe" R-thalidomide undergoes an in vivo chiral inversion to the "teratogenic" S-thalidomide.  Under biological conditions, the enantiomers interconvert (bidirectional chiral inversion – (R)- to (S)- and vice versa).[33] [34]

Chemistry

Thalidomide is racemic; while S-thalidomide is the bioactive form of the molecule, the individual enantiomers can racemize to each other due to the acidic hydrogen at the chiral centre, which is the carbon of the glutarimide ring bonded to the phthalimide substituent. The racemization process can occur in vivo.[4] [35] [36] [37] The process of conversion of one enantiomer to its mirror-image version with no other change in the molecule is called chiral inversion.[38]

Celgene Corporation originally synthesized thalidomide using a three-step sequence starting with L-glutamic acid treatment, but this has since been reformed by the use of L-glutamine.[39] As shown in the image below, N-carbethoxyphthalimide (1) can react with L-glutamine to yield N-phthaloyl-L-glutamine (2). Cyclization of N-phthaloyl-L-glutamine occurs using carbonyldiimidazole, which then yields thalidomide (3). Celgene Corporation's original method resulted in a 31% yield of S-thalidomide, whereas the two-step synthesis yields 85–93% product that is 99% pure.

In 2023, it is reported that phthalic anhydride and L-glutamine under suitable conditions can react directly to form thalidomide. In the procedure, phthalic anhydride and L-glutamine are grounded and added into toluene solvent. The solution, along with triethylamine and acetic anhydride, is refluxed at ~110°C for 9 hours; after that the solution goes though a simple vacuum filtration procedure to obtain the product.[40]

History

In 1952, thalidomide was synthesised by Chemical Industry Basel, but was found "to have no effect on animals" and was discarded on that basis.[41] In 1957, it was acquired by Chemie Grünenthal in Germany.[41] The German company had been established as a soap maker after World War II ended, to address the urgent market need for antibiotics.[42] Heinrich Mückter[43] was appointed to head the discovery program based on his experience working with the German army's antiviral research. While preparing reagents for the work, Mueckter's assistant Wilhelm Kunz isolated a by-product that was recognized by pharmacologist Herbert Keller as an analog of glutethimide, a sedative. The medicinal chemistry work turned to improving the lead compound into a suitable drug: the result was thalidomide. The toxicity was examined in several animals, and the drug was introduced in 1956 as a sedative, but it was never tested on pregnant women.[44]

Researchers at Chemie Grünenthal found that thalidomide was a particularly effective antiemetic that had an inhibitory effect on morning sickness.[45] On 1 October 1957, the company launched thalidomide and began marketing it under the trade name Contergan.[46] [47] It was proclaimed a "wonder drug" for insomnia, coughs, colds and headaches.[48]

During that period, the use of medications during pregnancy was not strictly controlled, and drugs were not thoroughly tested for potential harm to the fetus.[45] Thousands of pregnant women took the drug to relieve their symptoms. At the time of the drug's development, scientists did not believe any drug taken by a pregnant woman could pass across the placental barrier and harm the developing fetus.[49] There soon appeared reports of abnormalities in children being born to mothers using thalidomide. In late 1959, it was noticed that peripheral neuritis developed in patients who took the drug over a period of time, and it was only after this point that thalidomide ceased to be provided over the counter.[50]

While initially considered safe, the drug was responsible for teratogenic deformities in children born after their mothers used it during pregnancies, prior to the third trimester. In November 1961, thalidomide was taken off the market due to massive pressure from the press and public.[51] Experts estimate that thalidomide led to the death of approximately 2,000 children and serious birth defects in more than 10,000 children, with over half of them in West Germany.[52] The regulatory authorities in East Germany never approved thalidomide.[53] One reason for the initially unobserved side effects of the drug and the subsequent approval in West Germany was that at that time drugs did not have to be tested for teratogenic effects. They were tested for toxicity on rodents only, as was usual at the time.[54]

In the UK, the British pharmaceutical company The Distillers Company (Biochemicals) Ltd, a subsidiary of Distillers Co. Ltd (now part of Diageo plc), marketed thalidomide throughout the UK, Australia and New Zealand, under the brand name Distaval, as a remedy for morning sickness. Their advertisement claimed that "Distaval can be given with complete safety to pregnant women and nursing mothers without adverse effect on mother or child ... Outstandingly safe Distaval has been prescribed for nearly three years in this country."[53] Globally, more pharmaceutical companies started to produce and market the drug under license from Chemie Grünenthal. By the mid-1950s, 14 pharmaceutical companies were marketing thalidomide in 46 countries under at least 37 different trade names.

In the US, representatives from Chemie Grünenthal approached Smith, Kline & French (SKF), now GlaxoSmithKline, with a request to market and distribute the drug in North America. A memorandum, rediscovered in 2010 in the archives of the FDA, shows that in 1956–57, as part of its in-licensing approach, Smith, Kline and French conducted animal tests and ran a clinical trial of the drug in the US involving 875 people, including pregnant women.[55] In 1956, researchers involved in clinical trials at SKF noted that, even when used in very high doses, thalidomide could not induce sleep in mice. When administered at doses 50 to 650 times larger than that claimed by Chemie Grünenthal to be "sleep inducing", the researchers could still not achieve the hypnotic effect in animals that it had on humans. After completion of the trial, and based on reasons kept hidden for decades, SKF declined to commercialize the drug. In 1958, Chemie Grünenthal reached an agreement with the William S. Merrell Company in Cincinnati, Ohio (later Richardson-Merrell, now part of Sanofi), to market and distribute thalidomide throughout the US.[53]

The US FDA refused to approve thalidomide for marketing and distribution. However, the drug was distributed in large quantities for testing purposes, after the American distributor and manufacturer Richardson-Merrell had applied for its approval in September 1960. The official in charge of the FDA review, Frances Oldham Kelsey, did not rely on information from the company, which did not include any test results. Richardson-Merrell was called on to perform tests and report the results. The company demanded approval six times, and was refused each time. The distribution for "testing" resulted in 17 children born in the US with thalidomide-induced malformations. Oldham Kelsey was awarded the President's Award for Distinguished Federal Civilian Service by President Kennedy in 1962 for not allowing thalidomide to be approved for sale in the US. She was also inducted into the National Women's Hall of Fame in 2000.[56]

Canada's Food and Drug Directorate approved the sale of thalidomide by prescription in November, 1960.[57] There were many different forms sold: Kevadon, produced by the William S. Merrell Company seeking approval for its thalidomide product, was released on the market in April 1961, and the most common variant (Horner's Talimol) was put on the market on October 23 of the same year.[58] Two months after Talimol went on sale, pharmaceutical companies sent physicians letters warning about the risk of birth defects.[58] It was not until March 1962 that both drugs were banned from the Canadian market by the directorate, and soon afterward physicians were warned to destroy their supplies.[58]

Leprosy treatment

In 1964, Israeli physician Jacob Sheskin administered thalidomide to a patient critically ill with leprosy. The patient exhibited erythema nodosum leprosum (ENL), a painful skin condition, one of the complications of leprosy. The treatment was attempted despite the ban on thalidomide's use, and results were favourable: the patient slept for hours and was able to get out of bed without aid upon awakening. A clinical trial studying the use of thalidomide in leprosy soon followed.[59]

Thalidomide has been used by Brazilian physicians as the drug of choice for the treatment of severe ENL since 1965, and by 1996, at least 33 cases of thalidomide embryopathy were recorded in people born in Brazil after 1965.[60] Since 1994, the production, dispensing, and prescription of thalidomide have been strictly controlled, requiring women to use two forms of birth control and submit to regular pregnancy tests. Despite this, cases of thalidomide embryopathy continue,[61] [62] with at least 100 cases identified in Brazil between 2005 and 2010.[63] 5.8 million thalidomide pills were distributed throughout Brazil in this time period, largely to poor Brazilians in areas with little access to healthcare, and these cases have occurred despite the controls.

In 1998, the FDA approved the drug's use in the treatment of ENL.[64] Because of thalidomide's potential for causing birth defects, the drug may be distributed only under tightly controlled conditions. The FDA required that Celgene Corporation, which planned to market thalidomide under the brand name Thalomid, establish a system for thalidomide education and prescribing safety (STEPS) oversight program. The conditions required under the program include limiting prescription and dispensing rights to authorized prescribers and pharmacies only, keeping a registry of all patients prescribed thalidomide, providing extensive patient education about the risks associated with the drug, and providing periodic pregnancy tests for women who take the drug.[64]

In 2010, the World Health Organization stated that it did not recommend thalidomide for leprosy due to the difficulty of adequately controlling its use, and due to the availability of clofazimine.[65]

Cancer treatment

Shortly after the teratogenic properties of thalidomide were recognized in the mid-1960s, its anti-cancer potential was explored and two clinical trials were conducted in people with advanced cancer, including some people with multiple myeloma; the trials were inconclusive.[66]

Little further work was done with thalidomide in cancer until the 1990s.[66]

Judah Folkman pioneered studies into the role of angiogenesis (the proliferation and growth of blood vessels) in the development of cancer, and in the early 1970s had shown that solid tumors could not expand without it.[67] [68] In 1993 he surprised the scientific world by hypothesizing the same was true of blood cancers,[69] and the next year he published work showing that a biomarker of angiogenesis was higher in all people with cancer, but especially high in people with blood cancers, and other evidence emerged as well.[70] Meanwhile, a member of his lab, Robert D'Amato, who was looking for angiogenesis inhibitors, discovered in 1994 that thalidomide inhibited angiogenesis[71] and was effective in suppressing tumor growth in rabbits.[72] Around that time, the wife of a man who was dying of multiple myeloma and whom standard treatments had failed, called Folkman asking him about his anti-angiogenesis ideas.[68] Folkman persuaded the patient's doctor to try thalidomide, and that doctor conducted a clinical trial of thalidomide for people with multiple myeloma in which about a third of the subjects responded to the treatment.[68] The results of that trial were published in the New England Journal of Medicine in 1999.[68] [73]

After further work was done by Celgene and others, in 2006 the US Food and Drug Administration granted accelerated approval for thalidomide in combination with dexamethasone for the treatment of newly diagnosed multiple myeloma patients.[68] [74]

It was also evaluated whether thalidomide can be combined with melphalan and prednisone for patients with multiple myeloma. This combination of drugs probably results in an increase of the overall survival.[75]

Society and culture

Birth defect crisis

See main article: Thalidomide scandal. In the late 1950s and early 1960s, more than 10,000 children in 46 countries were born with deformities, such as phocomelia, as a consequence of thalidomide use.[76] The severity and location of the deformities depended on how many days into the pregnancy the mother was before beginning treatment, with the time-sensitive window occurring approximately between day 20 and day 36 post-fertilisation.[52] Thalidomide taken on the 20th day of pregnancy caused central brain damage, day 21 would damage the eyes, day 22 the ears and face, day 24 the arms, and leg damage would occur if taken up to day 28.

It is not known exactly how many worldwide victims of the drug there have been, although estimates range from 10,000 to 20,000.[77] Despite the side effects, thalidomide was sold in pharmacies in Canada until 1962.[58] [78]

Notable cases

Change in drug regulations

The disaster prompted many countries to introduce tougher rules for the testing and licensing of drugs, such as the 1962 Kefauver Harris Amendment[86] (US), 1965 Directive 65/65/EEC1 (EU),[87] and the Medicines Act 1968 (UK).[88] [89] In the United States, the new regulations strengthened the FDA, among other ways, by requiring applicants to prove efficacy and to disclose all side effects encountered in testing. The FDA subsequently initiated the Drug Efficacy Study Implementation to reclassify drugs already on the market.

Impact on research involving women

In 1977 the US Federal Drug Administration published a clinical trial guideline that excluded women of "childbearing potential" from the early phases of most clinical trials, which in practice led to their exclusion from later trial phases as well.[90] This 1977 FDA guideline was implemented in response to a protectionist climate caused by the thalidomide tragedy. In the 1980s, a US task force on women's health concluded that a lack of women's health research (in part due to the FDA guideline) had compromised the amount and quality of information available about diseases and treatments affecting women. This led to the National Institute of Health policy that women should, when beneficial, be included in clinical trials.

Quality of life

In the 1960s, thalidomide was successfully marketed as a safer alternative to barbiturates. Due to a successful marketing campaign, thalidomide was widely used by pregnant women during the first trimester of pregnancy. However, thalidomide is a teratogenic substance, and a proportion of children born during the 1960s had thalidomide embryopathy (TE).[91] Of these babies born with TE, "about 40% of them died before their first birthday".[92] The surviving individuals are now middle-aged and they report experiencing challenges (physical, psychological, and socioeconomic) related to TE.

Individuals born with TE frequently experience a wide variety of health problems secondary to their TE. These health conditions include both physical and psychological conditions. When compared to individuals of similar demographic profiles, those born with TE report less satisfaction with their quality of life and their overall health.[91] Access to health care services can also be a challenge for these people, and women in particular have experienced difficulty in locating healthcare professionals who can understand and embrace their needs.[92]

Brand names

Brand names include Contergan, Thalomid, Talidex, Talizer, Neurosedyn, Distaval and many others.

Research

Research efforts have been focused on determining how thalidomide causes birth defects and its other activities in the human body, efforts to develop safer analogs, and efforts to find further uses for thalidomide.

Thalidomide analogs

The exploration of the antiangiogenic and immunomodulatory activities of thalidomide has led to the study and creation of thalidomide analogs.[93] [94] Celgene has sponsored numerous clinical trials with analogues to thalidomide, such as lenalidomide, that are substantially more powerful and have fewer side effects — except for greater myelosuppression.[95] In 2005, Celgene received FDA approval for lenalidomide (Revlimid) as the first commercially useful derivative. Revlimid is available only in a restricted distribution setting to avoid its use during pregnancy. Further studies are being conducted to find safer compounds with useful qualities. Another more potent analog, pomalidomide, is now FDA approved.[96] Additionally, apremilast was approved by the FDA in March 2014. These thalidomide analogs can be used to treat different diseases, or used in a regimen to fight two conditions.[97]

Interest turned to pomalidomide, a derivative of thalidomide marketed by Celgene. It is a very active anti-angiogenic agent[94] and also acts as an immunomodulator. Pomalidomide was approved in February 2013 by the FDA as a treatment for relapsed and refractory multiple myeloma.[98] It received a similar approval from the European Commission in August 2013, and is expected to be marketed in Europe under the brand name Imnovid.[99]

Clinical research

There is no conclusive evidence that thalidomide or lenalidomide is useful to bring about or maintain remission in Crohn's disease.[100] [101]

Thalidomide was studied in a Phase II trial for Kaposi's sarcoma, a rare soft-tissue cancer most commonly seen in the immunocompromised, that is caused by the Kaposi's sarcoma-associated herpesvirus (KSHV).[102] [45]

Further reading

External links

Notes and References

  1. Web site: Thalomid- thalidomide capsule . DailyMed . 11 March 2021 . 21 October 2022 . 21 October 2022 . https://web.archive.org/web/20221021205855/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2eda833b-1357-4ed4-a093-194524fcb061 . live .
  2. Web site: Thalidomide BMS EPAR . European Medicines Agency . 17 September 2018 . 21 October 2022 . 21 October 2022 . https://web.archive.org/web/20221021205855/https://www.ema.europa.eu/en/medicines/human/EPAR/thalidomide-celgene . live .
  3. Web site: Thalidomide Lipomed EPAR . European Medicines Agency . 18 July 2022 . 21 October 2022 . 21 October 2022 . https://web.archive.org/web/20221021205902/https://www.ema.europa.eu/en/medicines/human/EPAR/thalidomide-lipomed . live .
  4. Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, Scheffler MA, Thomas SD, Laskin OL . Clinical pharmacokinetics of thalidomide . Clinical Pharmacokinetics . 43 . 5 . 311–27 . 2004 . 15080764 . 10.2165/00003088-200443050-00004 . 37728304 .
  5. Web site: Thalidomide Monograph for Professionals . Drugs.com . 14 November 2019 . en . 10 September 2012 . https://web.archive.org/web/20120910095924/https://www.drugs.com/monograph/thalidomide.html . live .
  6. Web site: Thalidomide Monograph for Professionals . 2023-02-04 . Drugs.com . en . 10 September 2012 . https://web.archive.org/web/20120910095924/https://www.drugs.com/monograph/thalidomide.html . live .
  7. Web site: Thalidomide C13H10N2O4 . CID 5426 . PubChem . . 13 February 2023 . 13 February 2023 . https://web.archive.org/web/20230213133343/https://pubchem.ncbi.nlm.nih.gov/compound/Thalidomide . live .
  8. Book: British national formulary : BNF 76. 2018. Pharmaceutical Press. 9780857113382. 936. 76.
  9. Book: The Oxford Companion to the Body . Cuthbert A . 2003 . Oxford University Press . 10.1093/acref/9780198524038.001.0001 . 9780198524038 . registration . 682 .
  10. Miller MT . Thalidomide embryopathy: a model for the study of congenital incomitant horizontal strabismus . Transactions of the American Ophthalmological Society . 89 . 623–74 . 1991 . 1808819 . 1298636 .
  11. Book: Loue S, Sajatovic M . Encyclopedia of Women's Health . 2004 . Springer Science & Business Media . 9780306480737 . 644 . en . 25 August 2020 . 15 November 2021 . https://web.archive.org/web/20211115114232/https://books.google.com/books?id=LbHWgd-mDbsC&pg=PA644 . live .
  12. Book: World Health Organization model list of essential medicines: 21st list 2019 . 2019. 10665/325771 . World Health Organization . Organization WH .
  13. Book: ((World Health Organization)) . World Health Organization model list of essential medicines: 22nd list (2021) . 2021 . 10665/345533 . World Health Organization . World Health Organization . Geneva . WHO/MHP/HPS/EML/2021.02 . free .
  14. Web site: First Generic Drug Approvals . U.S. Food and Drug Administration. 30 May 2023 . https://web.archive.org/web/20230630003621/https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/first-generic-drug-approvals . 30 June 2023 . live . 30 June 2023.
  15. Web site: Thalidomide Celgene 50 mg Hard Capsules - Summary of Product Characteristics . UK Electronic Medicines Compendium . 26 June 2017 . January 2017 . 30 August 2018 . https://web.archive.org/web/20180830210156/https://www.medicines.org.uk/emc/medicine/21005 . live .
  16. Web site: US Thalomid label . FDA . January 2017 . 26 June 2017 . 10 July 2017 . https://web.archive.org/web/20170710160759/https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020785s061lbl.pdf . live . For label updates see Web site: FDA index page for NDA 020785 . https://web.archive.org/web/20170629110300/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020785 . 29 June 2017 .
  17. Buonsenso D, Serranti D, Valentini P . Management of central nervous system tuberculosis in children: light and shade . European Review for Medical and Pharmacological Sciences . 14 . 10 . 845–53 . October 2010 . 21222370 . https://web.archive.org/web/20160818223324/http://www.europeanreview.org/wp/wp-content/uploads/827.pdf . 18 August 2016 .
  18. van Toorn R, Solomons R . Update on the diagnosis and management of tuberculous meningitis in children . Seminars in Pediatric Neurology . 21 . 1 . 12–8 . March 2014 . 24655399 . 10.1016/j.spen.2014.01.006 .
  19. Yang CS, Kim C, Antaya RJ . Review of thalidomide use in the pediatric population . Journal of the American Academy of Dermatology . 72 . 4 . 703–11 . April 2015 . 25617013 . 10.1016/j.jaad.2015.01.002 .
  20. Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB, Elad S, Lawitschka A, Socie G, Pavletic SZ, Holler E, Greinix H . Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD . Biology of Blood and Marrow Transplantation . 16 . 12 . 1611–28 . December 2010 . 20601036 . 10.1016/j.bbmt.2010.06.015 . free . 26 June 2017 . 29 August 2021 . https://web.archive.org/web/20210829083423/https://www.astctjournal.org/article/S1083-8791%2810%2900275-2/fulltext . live .
  21. Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang GB, Kobbe G, Gramatzki M, Lawitschka A, Mohty M, Pavletic SZ, Greinix H, Holler E . Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease . Biology of Blood and Marrow Transplantation . 17 . 1 . 1–17 . January 2011 . 20685255 . 10.1016/j.bbmt.2010.05.011 . free . 26 June 2017 . 29 August 2021 . https://web.archive.org/web/20210829083352/https://www.astctjournal.org/article/S1083-8791%2810%2900223-5/fulltext . live .
  22. Bermas BL . Paternal safety of anti-rheumatic medications . Best Practice & Research. Clinical Obstetrics & Gynaecology . 64 . 77–84 . April 2020 . 31727565 . 10.1016/j.bpobgyn.2019.09.004 . 208034967 .
  23. Smith SW . Chiral toxicology: it's the same thing...only different . Toxicological Sciences . 110 . 1 . 4–30 . July 2009 . 19414517 . 10.1093/toxsci/kfp097 . free .
  24. Anastas, P. T.; Warner, J. C. Green Chemistry: Theory and Practice, p3
  25. Web site: THALOMID® CAPSULES. TGA eBusiness Services. Celgene Pty Limited. 21 June 2013. 17 January 2014. PDF. 4 September 2015. https://web.archive.org/web/20150904052354/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-03581-3. live.
  26. Yamamoto J, Ito T, Yamaguchi Y, Handa H . Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders . Chemical Society Reviews . 51 . 15 . 6234–6250 . August 2022 . 35796627 . 10.1039/D2CS00116K . 250337170 . free .
  27. Stephens TD, Bunde CJ, Fillmore BJ . Mechanism of action in thalidomide teratogenesis . Biochemical Pharmacology . 59 . 12 . 1489–1499 . June 2000 . 10799645 . 10.1016/S0006-2952(99)00388-3 .
  28. Ito T, Handa H . Molecular mechanisms of thalidomide and its derivatives . Proceedings of the Japan Academy. Series B, Physical and Biological Sciences . 96 . 6 . 189–203 . 11 June 2020 . 32522938 . 7298168 . 10.2183/pjab.96.016 . 2020PJAB...96..189I .
  29. Asatsuma-Okumura T, Ando H, De Simone M, Yamamoto J, Sato T, Shimizu N, Asakawa K, Yamaguchi Y, Ito T, Guerrini L, Handa H . p63 is a cereblon substrate involved in thalidomide teratogenicity . Nature Chemical Biology . 15 . 11 . 1077–1084 . November 2019 . 31591562 . 10.1038/s41589-019-0366-7 . 203853198 .
  30. Gao S, Wang S, Song Y . Novel immunomodulatory drugs and neo-substrates . Biomarker Research . 8 . 1 . 2 . December 2020 . 31938543 . 6953231 . 10.1186/s40364-020-0182-y . free .
  31. Liu B, Su L, Geng J, Liu J, Zhao G . Developments in nonsteroidal antiandrogens targeting the androgen receptor . ChemMedChem . 5 . 10 . 1651–61 . October 2010 . 20853390 . 10.1002/cmdc.201000259 . 23228778 .
  32. Nuttall FQ, Warrier RS, Gannon MC . Gynecomastia and drugs: a critical evaluation of the literature . European Journal of Clinical Pharmacology . 71 . 5 . 569–78 . May 2015 . 25827472 . 4412434 . 10.1007/s00228-015-1835-x .
  33. Book: Stereochemical aspects of drug action and disposition . 2003 . Springer . Branch SK, Eichelbaum M, Testa B, Somogyi A . 978-3-540-41593-0 . Berlin . 52515592.
  34. Web site: Thalidomide . Chiralpedia . 20 August 2022 . 27 August 2022 . en-US . 27 August 2022 . https://web.archive.org/web/20220827093228/https://chiralpedia.com/blog/thalidomide/ . live .
  35. Eriksson T, Björkman S, Roth B, Fyge A, Höglund P . Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide . Chirality . 7 . 1 . 44–52 . 1995 . 7702998 . 10.1002/chir.530070109 .
  36. Man HW, Corral LG, Stirling DI, Muller GW . Alpha-fluoro-substituted thalidomide analogues . Bioorganic & Medicinal Chemistry Letters . 13 . 20 . 3415–7 . October 2003 . 14505639 . 10.1016/S0960-894X(03)00778-9 .
  37. Bartlett JB, Dredge K, Dalgleish AG . The evolution of thalidomide and its IMiD derivatives as anticancer agents . Nature Reviews. Cancer . 4 . 4 . 314–22 . April 2004 . 15057291 . 10.1038/nrc1323 . 7293027 .
  38. Wsól V, Skálová L, Szotáková B . Chiral inversion of drugs: coincidence or principle? . Current Drug Metabolism . 5 . 6 . 517–533 . December 2004 . 15578945 . 10.2174/1389200043335360 .
  39. Muller GW, Konnecke WE, Smith AM, Khetani VD . 19 March 1999. A Concise Two-Step Synthesis of Thalidomide . Organic Process Research & Development. 3. 2. 139–140. 10.1021/op980201b .
  40. Savini EB, Bandieri E . 2023 . One step synthesis of thalidomide . . en.
  41. Web site: Royal Pharmaceutical Society. The evolution of pharmacy, Theme E, Level 3 Thalidomide and its aftermath. 2011. https://web.archive.org/web/20141009110927/https://www.rpharms.com/museum-pdfs/e3a-thalidomide-and-its-aftermath-2011.pdf . 9 October 2014.
  42. Book: Rosett CM, Hagerty A . What History Can Teach us About Using Machine Learning Well . 2021 . Rosett CM, Hagerty A . Introducing HR Analytics with Machine Learning: Empowering Practitioners, Psychologists, and Organizations . 171–189 . Cham . Springer International Publishing . en . 10.1007/978-3-030-67626-1_10 . 978-3-030-67626-1 . 236710887 .
  43. News: Thomas K . The Unseen Survivors of Thalidomide Want to Be Heard. 23 March 2020. The New York Times. 23 March 2020. en-US. 0362-4331. 23 March 2020. https://web.archive.org/web/20200323154020/https://www.nytimes.com/2020/03/23/health/thalidomide-survivors-usa.html. live.
  44. Book: Sneader W . Drug discovery: a history. limited. 2005. Wiley. Chichester. 978-0-471-89979-2. 367. Rev. and updated.
  45. Franks ME, Macpherson GR, Figg WD . Thalidomide . Lancet . 363 . 9423 . 1802–11 . May 2004 . 15172781 . 10.1016/S0140-6736(04)16308-3 . 208789946 . 30 June 2019 . 21 August 2019 . https://web.archive.org/web/20190821212125/https://zenodo.org/record/1259793 . live .
  46. Web site: Grünenthal: Where we come from . https://web.archive.org/web/20180702093114/https://www.grunenthal.com/about-us/history . 2 July 2018 . 2 July 2018 . See also Web site: Developments regarding thalidomide . https://web.archive.org/web/20180702064501/http://www.contergan.grunenthal.info/thalidomid/Home_/351300028.jsp;jsessionid=D8966B9045A2EDE78D5AC41F85C93424.drp1?naviLocale=en_EN . 2 July 2018 .
  47. Moghe VV, Kulkarni U, Parmar UI . 2008 . Thalidomide . Bombay Hospital Journal . Bombay Hospital . Bombay . 50 . 3 . 472–6 . 8 August 2016 . 20 August 2016 . https://web.archive.org/web/20160820114658/http://www.bhj.org.in/journal/2008_5003_july/download/page-472-476.pdf . live .
  48. Campbell, Denis. "'Wonder drug' left babies with deformed limbs." The Guardian. 29 July 2009.
  49. Book: Heaton CA . The Chemical Industry . Springer . 1994 . 978-0-7514-0018-2 .
  50. Kelsey FO . Events after thalidomide . Journal of Dental Research . 46 . 6 . 1201–5 . 1967 . 5235007 . 10.1177/00220345670460061201 . 11175347 .
  51. Vargesson N, Stephens T . Thalidomide: history, withdrawal, renaissance, and safety concerns . Expert Opinion on Drug Safety . 20 . 12 . 1455–1457 . December 2021 . 34623196 . 10.1080/14740338.2021.1991307 . 238476677 . 2164/19455 . free .
  52. Vargesson N . Thalidomide-induced teratogenesis: history and mechanisms . Birth Defects Research. Part C, Embryo Today . 105 . 2 . 140–156 . June 2015 . 26043938 . 4737249 . 10.1002/bdrc.21096 .
  53. Web site: Hofland P . Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the "War" Against Cancer . Onco'Zine . December 2013 . 10 February 2018 . 11 February 2018 . https://web.archive.org/web/20180211072029/https://oncozine.com/reversal-of-fortune-how-a-vilified-drug-became-a-life-saving-agent-in-the-war-against-cancer/ . live .
  54. Web site: VFA: teratogenic effects . https://web.archive.org/web/20140104022807/http://www.vfa.de/de/arzneimittel-forschung/artikel-arzneimittel-forschung/teratogenitaet.html . 4 January 2014. 6 July 2011 .
  55. Web site: Lawsuit Blames Thalidomide for More Birth Defects . 2023-02-04 . Scientific American . en . 4 February 2023 . https://web.archive.org/web/20230204035126/https://www.scientificamerican.com/article/lawsuit-blames-thalidomide-for-more/ . live .
  56. Web site: Report . U.S. Food and Drug Administration . https://web.archive.org/web/20090512235601/https://www.fda.gov/fdac/features/2001/201_kelsey.html . 12 May 2009 . 12 May 2009 .
  57. News: Peritz I . The fight of their lives: After years of neglect, Canadian thalidomide survivors make a plea for help . 5 February 2023 . . November 21, 2014 . 5 February 2023 . https://web.archive.org/web/20230205215237/https://www.theglobeandmail.com/news/national/the-aftermath-of-thalidomide/article21689771/ . live .
  58. Webb JF . Canadian Thalidomide Experience . Canadian Medical Association Journal . 89 . 987–92 . November 1963 . 19 . 14076167 . 1921912 .
  59. Silverman WA . The schizophrenic career of a "monster drug" . Pediatrics . 110 . 2 Pt 1 . 404–6 . August 2002 . 12165600 . 10.1542/peds.110.2.404 .
  60. Castilla EE, Ashton-Prolla P, Barreda-Mejia E, Brunoni D, Cavalcanti DP, Correa-Neto J, Delgadillo JL, Dutra MG, Felix T, Giraldo A, Juarez N, Lopez-Camelo JS, Nazer J, Orioli IM, Paz JE, Pessoto MA, Pina-Neto JM, Quadrelli R, Rittler M, Rueda S, Saltos M, Sánchez O, Schüler L . Thalidomide, a current teratogen in South America . Teratology . 54 . 6 . 273–7 . December 1996 . 9098920 . 10.1002/(SICI)1096-9926(199702)55:2<156::AID-TERA6>3.0.CO;2-1 . free .
  61. Paumgartten FJ, Chahoud I . Thalidomide embryopathy cases in Brazil after 1965 . Reproductive Toxicology . 22 . 1 . 1–2 . July 2006 . 16427249 . 10.1016/j.reprotox.2005.11.007 . 2006RepTx..22....1P .
  62. Web site: Braziliense C . January 2006 . Talidomida volta a assustar . Thalidomide again scare . pt . dead . https://web.archive.org/web/20120313095445/http://www.saude.df.gov.br/003/00301009.asp?ttCD_CHAVE=31041 . 13 March 2012 .
  63. News: Brazil's new generation of Thalidomide babies . 23 July 2013 . Crawford A . BBC News . 21 June 2018 . 10 November 2020 . https://web.archive.org/web/20201110015129/https://www.bbc.com/news/magazine-23418102 . live .
  64. News: Thalidomide Approved to Treat Leprosy, With Other Uses Seen . New York Times . Stolberg SG . 8 January 2012 . 17 July 1998 . 3 December 2020 . https://web.archive.org/web/20201203003055/https://www.nytimes.com/1998/07/17/us/thalidomide-approved-to-treat-leprosy-with-other-uses-seen.html . live .
  65. Web site: Use of thalidomide in leprosy. https://web.archive.org/web/20061110083549/http://www.who.int/lep/research/thalidomide/en/index.html . dead . 10 November 2006 . Anon. WHO:leprosy elimination . WHO . 22 April 2010.
  66. Kyle RA, Rajkumar SV . Multiple myeloma . Blood . 111 . 6 . 2962–72 . March 2008 . 18332230 . 2265446 . 10.1182/blood-2007-10-078022 .
  67. Web site: Donahoe PK . Judah Folkman: 1933–2008. A Biographical Memoir . National Academy of Sciences . 2014 . 11 August 2015 . 2 August 2020 . https://web.archive.org/web/20200802184808/http://www.nasonline.org/publications/biographical-memoirs/memoir-pdfs/folkman-judah.pdf . live .
  68. Bielenberg DR, D'Amore PA . Judah Folkman's contribution to the inhibition of angiogenesis . Lymphatic Research and Biology . 6 . 3–4 . 203–7 . 2008 . 19093793 . 10.1089/lrb.2008.1016 .
  69. Folkman J . Angiogenesis-dependent diseases . Seminars in Oncology . 28 . 6 . 536–42 . December 2001 . 11740806 . 10.1016/s0093-7754(01)90021-1 .
  70. Ribatti D . Judah Folkman, a pioneer in the study of angiogenesis . Angiogenesis . 11 . 1 . 3–10 . 2008 . 18247146 . 2268723 . 10.1007/s10456-008-9092-6 .
  71. D'Amato RJ, Loughnan MS, Flynn E, Folkman J . Thalidomide is an inhibitor of angiogenesis . Proceedings of the National Academy of Sciences of the United States of America . 91 . 9 . 4082–5 . April 1994 . 7513432 . 43727 . 10.1073/pnas.91.9.4082 . 1994PNAS...91.4082D . free .
  72. Verheul HM, Panigrahy D, Yuan J, D'Amato RJ . Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits . British Journal of Cancer . 79 . 1 . 114–8 . January 1999 . 10408702 . 2362163 . 10.1038/sj.bjc.6690020 .
  73. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B . Antitumor activity of thalidomide in refractory multiple myeloma . The New England Journal of Medicine . 341 . 21 . 1565–71 . November 1999 . 10564685 . 10.1056/NEJM199911183412102 . free .
  74. Web site: FDA Approval for Thalidomide. National Cancer Institute. 8 January 2012. 28 January 2012. https://web.archive.org/web/20120128120343/http://www.cancer.gov/cancertopics/druginfo/fda-thalidomide. dead.
  75. Piechotta V, Jakob T, Langer P, Monsef I, Scheid C, Estcourt LJ, Ocheni S, Theurich S, Kuhr K, Scheckel B, Adams A, Skoetz N . Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis . The Cochrane Database of Systematic Reviews . 2019 . 11 . November 2019 . 31765002 . 10.1002/14651858.CD013487 . 6876545 . Cochrane Haematology Group .
  76. News: Bren L . Frances Oldham Kelsey: FDA Medical Reviewer Leaves Her Mark on History . FDA Consumer . . 28 February 2001 . 23 December 2009 . 29 June 2011 . https://web.archive.org/web/20110629135137/http://permanent.access.gpo.gov/lps1609/www.fda.gov/fdac/features/2001/201_kelsey.html . live .
  77. News: Zimmer C . Answers Begin to Emerge on How Thalidomide Caused Defects . As they report in the current issue of Science, a protein known as cereblon latched on tightly to the thalidomide . . 15 March 2010 . 21 March 2010 . Carl Zimmer . 23 March 2010 . https://web.archive.org/web/20100323152804/http://www.nytimes.com/2010/03/16/science/16limb.html . live .
  78. Web site: Turning Points of History–Prescription for Disaster . History Television . 24 February 2010 . dead . https://web.archive.org/web/20110929135332/http://www.history.ca/ontv/titledetails.aspx?titleid=21267 . 29 September 2011 .
  79. News: Tamplin H . Mid Sussex residents honoured by Queen . Mid Sussex Times . 12 June 2015 . 27 December 2015 . 2 January 2016 . https://web.archive.org/web/20160102040642/http://www.midsussextimes.co.uk/news/local/mid-sussex-residents-honoured-by-queen-1-6795898 . live .
  80. Web site: Orpheus lives: A small good thing in Quastoff . The Portland Phoenix . 19 April 2002 . 6 June 2013 . dead . https://web.archive.org/web/20120306201745/https://www.portlandphoenix.com/archive/music/02/04/19/classical_Orpheus.html . 6 March 2012 .
  81. Web site: NoBody's Perfect (2008): Release Info . IMDB . 6 June 2013 . 23 June 2013 . https://web.archive.org/web/20130623182019/http://www.imdb.com/title/tt1266093/releaseinfo . live .
  82. Web site: Film Review: NoBody's Perfect . Brussat F, Brussat MA . Spirituality & Practice . 6 June 2013 . 9 May 2013 . https://web.archive.org/web/20130509033726/http://www.spiritualityandpractice.com/films/films.php?id=19559 . live .
  83. Web site: . Outstanding eight to receive honorary doctorates at Convocation. Daily News. University of Windsor. 6 March 2017. Windsor, Ontario, Canada. 9 June 2016. 7 March 2017. https://web.archive.org/web/20170307123542/http://www.uwindsor.ca/dailynews/2016-06-07/outstanding-eight-receive-honorary-doctorates-convocation. live.
  84. Mitchell D, Snyder S . Exploitations of embodiment: Born Freak and the academic bally plank. . Disability Studies Quarterly . June 2005 . 25 . 3 . 10.18061/dsq.v25i3.575 . free . 30 May 2019 . 23 October 2020 . https://web.archive.org/web/20201023214836/https://dsq-sds.org/article/view/575/752 . live .
  85. The Thalidomide Trust, Sue Kent's Garden Featured on the BBC, 16 September 2020. https://www.thalidomidetrust.org/sue-kents-garden-featured-on-the-bbc/
  86. Web site: 50 Years: The Kefauver-Harris Amendments. Food and Drug Administration (United States). 6 June 2013. 7 March 2013. https://web.archive.org/web/20130307165433/http://www.fda.gov/Drugs/NewsEvents/ucm320924.htm. live.
  87. Web site: Thalidomide . . 6 June 2013 . dead . https://web.archive.org/web/20131203020225/http://www.crncc.nihr.ac.uk/workforce_development/learning_and_development/gcp/gcp_resource/research_standards/history/thalidomide . 3 December 2013 .
  88. Conroy S, McIntyre J, Choonara I . Unlicensed and off label drug use in neonates . Archives of Disease in Childhood. Fetal and Neonatal Edition . 80 . 2 . F142-4; discussion F144-5 . March 1999 . 10325794 . 1720896 . 10.1136/fn.80.2.F142 .
  89. Web site: Royal Pharmaceutical Society . The evolution of pharmacy, Theme E, Level 3 Thalidomide and its aftermath . https://web.archive.org/web/20111014114005/https://www.rpharms.com/museum-pdfs/e3a-thalidomide-and-its-aftermath-2011.pdf . dead . 14 October 2011 . 2011 .
  90. Merkatz RB . Inclusion of women in clinical trials: a historical overview of scientific, ethical, and legal issues . Journal of Obstetric, Gynecologic, and Neonatal Nursing . 27 . 1 . 78–84 . January 1998 . 9475131 . 10.1111/j.1552-6909.1998.tb02594.x . free .
  91. Newbronner E, Glendinning C, Atkin K, Wadman R . The health and quality of life of Thalidomide survivors as they age - Evidence from a UK survey . PLOS ONE . 14 . 1 . e0210222 . 16 January 2019 . 30650111 . 6334953 . 10.1371/journal.pone.0210222 . 2019PLoSO..1410222N . free .
  92. Nippert I, Edler B, Schmidt-Herterich C . 40 years later: the health related quality of life of women affected by thalidomide . Community Genetics . 5 . 4 . 209–16 . 2002 . 14960874 . 10.1159/000066691 . 29641011 .
  93. Shah JH, Swartz GM, Papathanassiu AE, Treston AM, Fogler WE, Madsen JW, Green SJ . Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis . Journal of Medicinal Chemistry . 42 . 16 . 3014–7 . August 1999 . 10447943 . 10.1021/jm990083y .
  94. D'Amato RJ, Lentzsch S, Anderson KC, Rogers MS . Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma . Seminars in Oncology . 28 . 6 . 597–601 . December 2001 . 11740816 . 10.1016/S0093-7754(01)90031-4 .
  95. Rao KV . Lenalidomide in the treatment of multiple myeloma . American Journal of Health-System Pharmacy . 64 . 17 . 1799–807 . September 2007 . 17724360 . 10.2146/ajhp070029 .
  96. Web site: Search of: pomalidomide. Clinicaltrials.gov. 1 September 2012. 3 July 2015. https://web.archive.org/web/20150703130302/https://clinicaltrials.gov/ct/search?term=pomalidomide&submit=Search. live.
  97. Raghupathy R, Billett HH . Promising therapies in sickle cell disease . Cardiovascular & Hematological Disorders Drug Targets . 9 . 1 . 1–8 . March 2009 . 19275572 . 10.2174/187152909787581354 .
  98. Web site: Pomalyst (Pomalidomide) Approved By FDA For Relapsed And Refractory Multiple Myeloma. The Myeloma Beacon. 10 August 2013. 7 January 2014. https://web.archive.org/web/20140107033928/http://www.myelomabeacon.com/news/2013/02/08/pomalyst-pomalidomide-fda-approval-multiple-myeloma/. live.
  99. Web site: Pomalidomide Approved In Europe For Relapsed And Refractory Multiple Myeloma. The Myeloma Beacon. 10 August 2013. 18 January 2014. https://web.archive.org/web/20140118140152/http://www.myelomabeacon.com/news/2013/08/09/pomalidomide-imnovid-pomalyst-europe-ema-approval-multiple-myeloma/. live.
  100. Srinivasan R, Akobeng AK . Thalidomide and thalidomide analogues for induction of remission in Crohn's disease . The Cochrane Database of Systematic Reviews . 2 . CD007350 . April 2009 . 19370684 . 10.1002/14651858.CD007350.pub2 .
  101. Akobeng AK, Stokkers PC . Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease . The Cochrane Database of Systematic Reviews . 2 . CD007351 . April 2009 . 2009 . 19370685 . 7207562 . 10.1002/14651858.CD007351.pub2 .
  102. Web site: Kaposi Sarcoma Treatment & Management . Medscape Reference . WebMD . 11 March 2013 . 19 January 2014 . Rose LJ, Fishman AD, Sparano JA . Talavera F, McKenna R, Harris JE . 2 February 2014 . https://web.archive.org/web/20140202145013/http://emedicine.medscape.com/article/279734-treatment#showall . live .
  103. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM . Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial . Gut . 54 . 4 . 540–5 . April 2005 . 15753541 . 1774430 . 10.1136/gut.2004.047563 .
  104. Sharpstone D, Rowbottom A, Francis N, Tovey G, Ellis D, Barrett M, Gazzard B . Thalidomide: a novel therapy for microsporidiosis . Gastroenterology . 112 . 6 . 1823–9 . June 1997 . 9178672 . 10.1053/gast.1997.v112.pm9178672 . free .
  105. Tunio MA, Hashmi A, Qayyum A, Naimatullah N, Masood R . Low-dose thalidomide in patients with metastatic renal cell carcinoma . The Journal of the Pakistan Medical Association . 62 . 9 . 876–9 . September 2012 . 23139966 .
  106. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H . Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial . Annals of Internal Medicine . 128 . 6 . 443–50 . March 1998 . 9499327 . 10.7326/0003-4819-128-6-199803150-00004 . 12089634 .
  107. Wallis RS, Hafner R . Advancing host-directed therapy for tuberculosis . Nature Reviews. Immunology . 15 . 4 . 255–63 . April 2015 . 25765201 . 10.1038/nri3813 . 1452130 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Thalidomide".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.